8 June 2021 - It has all the makings of a bombastic drug pricing debate: a highly anticipated drug, widespread press attention, a huge potential patient population, and a price higher than even some of the highest Wall Street estimates.

But when Biogen announced Monday it would charge $56,000 for an annual course of its just approved Alzheimer’s treatment, the activists who are normally eager to criticise pharma and its pricing strategies were largely silent.

Read Stat News article